USD 5.44
(6.67%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 136.49 Million USD | 69.96% |
2022 | 77.87 Million USD | 22.59% |
2021 | 63.52 Million USD | 12.09% |
2020 | 56.66 Million USD | -63.18% |
2019 | 153.92 Million USD | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q1 | 32.38 Million USD | 23.38% |
2024 Q2 | 26.59 Million USD | -14.76% |
2023 Q1 | 32.46 Million USD | 19.59% |
2023 Q4 | 26.24 Million USD | -42.35% |
2023 Q3 | 45.53 Million USD | 45.84% |
2023 FY | 132.34 Million USD | 69.96% |
2023 Q2 | 31.21 Million USD | -3.84% |
2022 Q2 | 17.86 Million USD | 23.45% |
2022 Q1 | 14.47 Million USD | 3660.89% |
2022 FY | 77.87 Million USD | 22.59% |
2022 Q3 | 18.38 Million USD | 2.88% |
2022 Q4 | 27.14 Million USD | 47.68% |
2021 Q4 | 384.85 Thousand USD | 35.83% |
2021 Q1 | -15.88 Million USD | -12.09% |
2021 Q3 | 283.34 Thousand USD | 101.78% |
2021 FY | 63.52 Million USD | 12.09% |
2021 Q2 | -15.88 Million USD | 0.0% |
2020 Q3 | -14.16 Million USD | 0.0% |
2020 Q1 | -14.16 Million USD | 63.18% |
2020 FY | 56.66 Million USD | -63.18% |
2020 Q4 | -14.16 Million USD | 0.0% |
2020 Q2 | -14.16 Million USD | 0.0% |
2019 Q3 | -38.48 Million USD | 0.0% |
2019 Q4 | -38.48 Million USD | 0.0% |
2019 FY | 153.92 Million USD | 0.0% |
2019 Q2 | -38.48 Million USD | 0.0% |
2019 Q1 | -38.48 Million USD | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Amgen Inc. | 11.87 Billion USD | 98.851% |
AstraZeneca PLC | 29.57 Billion USD | 99.539% |
Biogen Inc. | 5.2 Billion USD | 97.378% |
Gilead Sciences, Inc. | 13.01 Billion USD | 98.951% |
MIRA Pharmaceuticals, Inc. | 8.52 Million USD | -1500.894% |
Scilex Holding Company | 136.49 Million USD | 0.0% |